News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
747,677 Results
Type
Article (51481)
Company Profile (328)
Press Release (695868)
Section
Business (218924)
Career Advice (2606)
Deals (37997)
Drug Delivery (110)
Drug Development (85285)
Employer Resources (178)
FDA (17034)
Job Trends (16030)
News (369960)
Policy (35615)
Tag
Academia (2762)
Alliances (54005)
Alzheimer's disease (1346)
Approvals (16987)
Artificial intelligence (212)
Bankruptcy (372)
Best Places to Work (12113)
Biotechnology (211)
Breast cancer (224)
Cancer (1675)
Cardiovascular disease (134)
Career advice (2188)
CAR-T (122)
Cell therapy (354)
Clinical research (68308)
Collaboration (658)
Compensation (338)
COVID-19 (2741)
C-suite (150)
Data (1547)
Diabetes (208)
Diagnostics (6493)
Earnings (89914)
Employer resources (156)
Events (118634)
Executive appointments (556)
FDA (17892)
Funding (588)
Gene therapy (249)
GLP-1 (717)
Government (4735)
Healthcare (19738)
Infectious disease (2846)
Inflammatory bowel disease (126)
Interviews (448)
IPO (16934)
Job creations (4375)
Job search strategy (1843)
Layoffs (478)
Legal (8941)
Lung cancer (246)
Manufacturing (248)
Medical device (13794)
Medtech (13799)
Mergers & acquisitions (21380)
Metabolic disorders (564)
Neuroscience (1767)
NextGen: Class of 2025 (7037)
Non-profit (4796)
Northern California (1969)
Obesity (320)
Opinion (241)
Patents (146)
People (60742)
Phase I (21133)
Phase II (29910)
Phase III (22568)
Pipeline (662)
Postmarket research (2900)
Preclinical (9117)
Radiopharmaceuticals (255)
Rare diseases (329)
Real estate (6566)
Regulatory (23663)
Research institute (2481)
Resumes & cover letters (423)
Southern California (1710)
Startups (3883)
United States (17967)
Vaccines (653)
Weight loss (237)
Date
Today (154)
Last 7 days (655)
Last 30 days (2996)
Last 365 days (36315)
2025 (3123)
2024 (36755)
2023 (41381)
2022 (52637)
2021 (57362)
2020 (56114)
2019 (49175)
2018 (37256)
2017 (34553)
2016 (34578)
2015 (40531)
2014 (34794)
2013 (30322)
2012 (32189)
2011 (32632)
2010 (31076)
Location
Africa (929)
Arizona (216)
Asia (43145)
Australia (7059)
California (4542)
Canada (1639)
China (388)
Colorado (209)
Connecticut (225)
Europe (94249)
Florida (654)
Georgia (160)
Illinois (475)
Indiana (262)
Maryland (737)
Massachusetts (3565)
Michigan (195)
Minnesota (328)
New Jersey (1302)
New York (1307)
North Carolina (864)
Northern California (1969)
Ohio (169)
Pennsylvania (1055)
South America (1323)
Southern California (1710)
Texas (660)
Utah (134)
Washington State (452)
747,677 Results for "aragon pharmaceuticals inc acquired by johnson and johnson".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Proteologix, Inc. to be Acquired by Johnson & Johnson
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson
May 16, 2024
·
2 min read
Press Releases
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
January 13, 2025
·
20 min read
Deals
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Acquisition advances Johnson & Johnson’s leading Dermatology portfolio with opportunity to address significant unmet need in atopic dermatitis (AD).
May 16, 2024
·
8 min read
Deals
Johnson & Johnson to Acquire Shockwave Medical
Johnson & Johnson and Shockwave Medical, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
April 5, 2024
·
15 min read
Press Releases
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
January 23, 2025
·
19 min read
Press Releases
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
February 3, 2025
·
1 min read
Deals
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
Numab Therapeutics AG announced that the Company has entered into a definitive agreement whereby Johnson & Johnson acquires Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab to be spun-off to Numab’s shareholders.
May 28, 2024
·
3 min read
Deals
Johnson & Johnson Completes Acquisition of Shockwave Medical
Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson MedTech.
May 31, 2024
·
5 min read
Mergers & acquisitions
Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout
Among Intra-Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.
January 13, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour
January 23, 2025
·
13 min read
1 of 74,768
Next
